RA Capital Nexus Fund III, L.P.
Director; Director, 10% Owner · 8 filings · Latest: May 11, 2026
Artiva Biotherapeutics, Inc.
Bicara Therapeutics Inc.
Climb Bio, Inc.
Evommune, Inc.
Mineralys Therapeutics, Inc.
SpyGlass Pharma, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ARTV | RA Capital Nexus Fund III, L.P. | Director | May 11, 2026 | Purchase | $11.52 | 6,510,416 | $75.0M | 15,203,995 | |
MLYS | RA Capital Nexus Fund III, L.P. | Director | Mar 30, 2026 | Purchase | $24.16 | 58,300 | $1.4M | 5,825,521 | |
MLYS | RA Capital Nexus Fund III, L.P. | Director | Mar 27, 2026 | Purchase | $23.67 | 310,700 | $7.4M | 5,767,221 | |
BCAX | RA Capital Nexus Fund III, L.P. | Director | Feb 26, 2026 | Purchase | $16.00 | 300,000 | $4.8M | 4,603,418 | |
SGP | RA Capital Nexus Fund III, L.P. | Director | Feb 9, 2026 | Purchase | $16.00 | 3,690,000 | $59.0M | 2,054,678 | |
SION | RA Capital Nexus Fund III, L.P. | — | Nov 21, 2025 | Proposed Sale | $43.66 | 6,440 | $281.2K | — | |
SION | RA Capital Nexus Fund III, L.P. | — | Nov 20, 2025 | Proposed Sale | $38.94 | 1,313 | $51.1K | — | |
SION | RA Capital Nexus Fund III, L.P. | — | Nov 19, 2025 | Proposed Sale | $38.41 | 12,134 | $466.1K | — | |
SION | RA Capital Nexus Fund III, L.P. | — | Nov 18, 2025 | Proposed Sale | $39.04 | 1,770 | $69.1K | — | |
SION | RA Capital Nexus Fund III, L.P. | — | Nov 17, 2025 | Proposed Sale | $39.93 | 20,969 | $837.3K | — | |
SION | RA Capital Nexus Fund III, L.P. | — | Oct 28, 2025 | Proposed Sale | $39.45 | 17,118 | $675.3K | — | |
SION | RA Capital Nexus Fund III, L.P. | — | Oct 24, 2025 | Proposed Sale | $39.21 | 66,672 | $2.6M | — |